70 60

Cited 0 times in

아토피피부염 환자에서 국소 tacrolimus 0.1%에 대한 약물정보지 제공의 효과 및 국소 tacrolimus 0.1% 효능과 환자의 순응도 평가

DC FieldValueLanguage
dc.contributor.author박창욱-
dc.contributor.author이주희-
dc.date.accessioned2018-05-10T06:43:45Z-
dc.date.available2018-05-10T06:43:45Z-
dc.date.issued2013-
dc.identifier.issn2288-0402-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/158520-
dc.description.abstractPurpose: Topical calcineurin inhibitor is recently developed topical immunomodulator, and preliminary studies showed its effectiveness in the treatment of atopic dermatitis (AD). However, some side effects including transient irritation can influence the patient compliance. So, there are some needs to improve the patient compliance. The purpose of this study was to evaluate the efficacy, safety and patient compliance with using topical tacrolimus 0.1% to treat AD when the correct information about topical tacrolimus are properly given to patients. Methods: We examined the medical recordings, clinical severity scoring of total 194 AD patients at 9 general hospitals in Seoul, Korea from September 2010 to August 2011. We offered an infosheet of topical tacrolimus 0.1% and the patients applied it twice a day for 2 weeks. And we measured the efficacy of the topical tacrolimus 0.1% with SCORing atopic dermatitis (SCORAD) index, patient’s global assessment (PGA), and investigator’s global assessment (IGA). Results: Topical tacrolimus 0.1% effectively controlled AD with a reduction of the SCORAD index from baseline 31.9 to 20.2 at 2 weeks of application. In IGA results showed 98% got improvement and in PGA, results showed 96% got improvement after treatment. Although 42.3% of the patients complained of adverse effects, these were all transient. The effect of information on topical tacrolimus 0.1% showed 34% patients could predict the side effect, 35% patients could feel safety to use, and 18% patients experienced side effect but could maintain topical calcineurin inhibitor. Conclusion: Topical tacrolimus 0.1% may be an effective treatment modality for AD when patients show good compliance for applying the ointment. And properly given, the correct information may increase the patient compliance.-
dc.description.statementOfResponsibilityopen-
dc.publisherKorean Academy of Pediatric Allergy and Respiratory Disease-
dc.relation.isPartOfAllergy Asthma & Respiratory Disease-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.title아토피피부염 환자에서 국소 tacrolimus 0.1%에 대한 약물정보지 제공의 효과 및 국소 tacrolimus 0.1% 효능과 환자의 순응도 평가-
dc.title.alternativeEffect of infosheet for topical tacrolimus 0.1% and its efficacy and compliance in the treatment of atopic dermatitis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Dermatology-
dc.contributor.googleauthor한지수-
dc.contributor.googleauthor이우진-
dc.contributor.googleauthor고주연-
dc.contributor.googleauthor김정수-
dc.contributor.googleauthor김상석-
dc.contributor.googleauthor서수홍-
dc.contributor.googleauthor유박린-
dc.contributor.googleauthor이가영-
dc.contributor.googleauthor이주희-
dc.contributor.googleauthor박창욱-
dc.contributor.googleauthor장상재-
dc.contributor.googleauthor박현수-
dc.identifier.doi10.4168/aard.2013.1.3.221-
dc.contributor.localIdA01716-
dc.contributor.localIdA03171-
dc.relation.journalcodeJ00065-
dc.subject.keywordAtopic dermatitis-
dc.subject.keywordTopical calcineurin inhibitor-
dc.subject.keywordTopical tacrolimus 0.1%-
dc.subject.keywordInformation-
dc.contributor.alternativeNamePark, Chang Ook-
dc.contributor.alternativeNameLee, Ju Hee-
dc.contributor.affiliatedAuthorPark, Chang Ook-
dc.contributor.affiliatedAuthorLee, Ju Hee-
dc.citation.volume1-
dc.citation.number3-
dc.citation.startPage221-
dc.citation.endPage226-
dc.identifier.bibliographicCitationAllergy Asthma & Respiratory Disease, Vol.1(3) : 221-226, 2013-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.